Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Italian researchers find fenretinide cuts the risk of second breast cancers in young women

04.05.2006


A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] – a drug related to vitamin A – significantly cuts the risk of a second breast cancer among younger patients.



The Italian research team reporting the findings on-line today (Thursday 4 May) in Annals of Oncology[2], are sufficiently convinced of the drug’s protective potential to call for a trial to test its use as a preventive in pre-menopausal healthy women at high risk of the disease. They are now seeking international partners and funding for such a trial.

The women in the long-term follow-up comprised a sub-group of 1,700 – 60% of the patients in a 10-centre trial lead by Professor Umberto Veronesi and co-ordinated by Milan’s Istituto Nazionale Tumori when he was its director. The study, which began in 1987, randomised more than 2,800 women to receive 200 mg fenretinide daily for five years or no extra treatment after surgery for early-stage breast cancer.


The new analysis, also lead by Professor Veronesi, who is now Director of the European Institute of Oncology in Milan, followed the 1,739 patients who had been recruited by the Istituto Nazionale Tumori centre, investigating whether these patients developed a second cancer either in the treated breast or the other breast.

Co-author Dr Andrea Decensi, Director of the Department of Medical Oncology at the Galliera Hospital in Genoa, said: “We followed these patients for between 12 and 16 years and we found 168 second breast cancers in the fenretinide arm and 190 in the control arm. In post-menopausal women there were actually more cancers in the fenretinide arm than among the controls (85 as against 64). But, among pre-menopausal women there were only 83 second cancers in the fenretinide group compared with 126 in the control group.

Dr Decensi said that overall, this meant a 17% reduction in second cancers among the fenretinide group, which was of borderline statistical significance. But, there were four really strong messages within that overall finding:

• fenretinide had different effects on post-menopausal and pre-menopausal women and the increase in second breast cancers among post-menopausal women in the fenretinide arm meant it should not be given to that age group;

• it produced a statistically significant 38% reduction in second breast cancers in pre-menopausal women and halved the risk in women under 40;

• the protection in pre-menopausal women still persisted at 15 years follow-up even though the drug was given for only five years;

• the drug was effective in pre-menopausal women against both oestrogen receptor positive and oestrogen receptor negative breast cancer

Professor Veronesi said that fenretinide appeared to work by re-imposing order on breast cells that were in the process of becoming disorganised and growing out of control and also by forcing those that were in danger of becoming immortal to undergo normal cell death (apoptosis).

He said that the study had the limitation of being a retrospective sub-group analysis, so it needed to be updated and confirmed by results for the other 40% of patients, which they planned to do if funds became available.

“This sub-group analysis had not been foreseen when the original study was planned, so our findings are therefore hypothesis generating. It means that we are not in a position to make clinical recommendations from these data alone, but that this evidence provides a rationale for a new trial in young women at high risk of breast cancer. However, the magnitude of the effect, and the finding that the younger the woman the greater was the benefit, is so striking that we believe it is likely to be real.”

The researchers also want studies to discover exactly how the drug works because the biological mechanisms are still unclear, especially the reasons why it works differently in younger or older women. They suggest that fenretinide may enhance the protective or damaging effects of hormones in different ways according to the stage of breast gland development in women.

Said Dr Decensi: “Its differential effect recalls the effect of first full term pregnancy on breast cancer risk, which is protective at a young age and deleterious at an older age.”

He said the team wanted to initiate a prevention trial in young high-risk women, which would also look at the drug’s potential for preventing ovarian cancer where there was some existing evidence that it may also be effective. They hoped that it might be possible to undertake it as a multi-centre international Europe/USA collaboration.

Professor Guiseppe De Palo from the Istituto Nazionale, who co-ordinated the study, explained that women carrying the BRCA-1 and 2 ‘breast cancer’ genes, which also confer a higher risk of ovarian cancer, would be ideal candidates for a prevention trial. The drug had few side effects although there were still concerns that it could be harmful to unborn babies, which meant young women taking part must use reliable contraception.

“Fenretinide is something of a Cinderella drug,” he said. “Like other retinoids it is tricky to manufacture because it is difficult to maintain the stability of the formulation and there are problems of pharmacological interactions. So, the pharmaceutical industry was reluctant to risk investing in its long-term clinical research, especially given that the patent would run out and tamoxifen was already on the market for treatment and had more efficacy data from large international trials.”

Dr Decensi added that a preventive trial of fenretinide would be a clear example of the importance of health-care provider and community support for not-for-profit academic clinical research with older compounds. These were often safer than new agents for which long-term safety – a crucial issue in prevention – was still unknown.

[1] Fenretinide: A synthetic retinoid – analogue of retinol (vitamin A), which binds to and activates retinoic acid receptors, inducing cell differentiation and cell death in some tumour types. It also inhibits tumour growth by modulating the growth factors associated with blood vessel development.

[2] Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Annals of Oncology. doi”10.1093/annonc/mdl047.

Margaret Willson | alfa
Further information:
http://www.oup.com

More articles from Health and Medicine:

nachricht TSRI researchers develop new method to 'fingerprint' HIV
29.03.2017 | Scripps Research Institute

nachricht Periodic ventilation keeps more pollen out than tilted-open windows
29.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers shoot for success with simulations of laser pulse-material interactions

29.03.2017 | Materials Sciences

Igniting a solar flare in the corona with lower-atmosphere kindling

29.03.2017 | Physics and Astronomy

As sea level rises, much of Honolulu and Waikiki vulnerable to groundwater inundation

29.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>